A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis
-
- STATUS
- Recruiting
Summary
This is a 24-week randomized, double blind, placebo controlled, parallel group, dose ranging, Phase 2b study designed to assess the efficacy of different doses and dose regimens of Etokimab compared to placebo in adult subjects with moderate to severe atopic dermatitis (AD).
This study will also assess the safety, tolerability, and pharmacokinetics of Etokimab. The study will have a total of 11 in-office visits (there is a 4-week screening period when some tests and assessments will be done to see if the study is suitable for you, followed by a 16-week treatment period, where you will attend the study center 8 times, then there will be an 8-week safety follow-up period, where you will attend the study center twice).
Visits throughout the study include a physical exam, blood draws, urine sampling, ECG’s, assessments, and administration of study drug subcutaneously (SC) during selected onsite visits by qualified professionals and other assessments which will be reviewed in detail at your screening visit.
All services are provided at no cost.
Description
- Physical exam and assessments of study condition to be provided at no cost by an experienced provider.
- No insurance necessary.
- Compensation will be provided at the end of study participation.
Details
| Condition | Skin Infections/Disorders, Atopic Dermatitis, Eczema (Atopic Dermatitis), Dermatitis - Atopic, Dermatitis, Atopic |
|---|---|
| Clinical Study Identifier | TX218128 |
| Last Modified on | 23 November 2020 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer